CCL2 and hyperinsulinism: Rosiglitazone treatment reduced hyperinsulinemia (DIO 4510 +/− 490 pg/ml: DIO-Rosi 2170 +/− 620 pg/ml), serum CCL2 levels (DIO 84.2 +/− 0.18 pg/ml: DIO-Rosi 47.3 +/− 4.6 pg/ml) and SVF mediator production of IL-6, TNFα, IL-1β and IL-10 (Figure 6(b)).